CSL News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

02.06.22	Seqirus' Holly Springs Manufacturing Facility Designated by U.S. Government as Pandemic Ready (PR Newswire)
24.05.22	FDA Accepts CSL Behring's Biologics License Application for Etranacogene Dezaparvovec for Priority Review (PR Newswire)
11.05.22	Walter Charles Named Senior Vice President and General Manager of CSL Plasma (PR Newswire)
28.04.22	CSL Behring Donates 500 Million International Units of Coagulation Factor Replacement Therapy to the World Federation of Hemophilia Humanitarian Aid Program to Help Those Living with Bleeding Diso... (PR Newswire)
28.03.22	European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B (PR Newswire)
02.03.22	Forbes Magazine Ranks Global Biotech Leader CSL Among America's Best Employers for 2022 (PR Newswire)
25.02.22	Seqirus and U.S. Government Renew Multi-Year Agreement for Influenza Pandemic Preparedness and Response (PR Newswire)
22.02.22	CSL Plasma Makes $125,000 Donation to American Red Cross for Disaster Relief in U.S. Communities (PR Newswire)
07.02.22	Seqirus, a Business of CSL Limited, Announces New Facility Supporting Research & Development of Leading-Edge Influenza Vaccine Technology (PR Newswire)
04.02.22	Final Analysis of Pivotal HOPE-B Study Demonstrates Durable and Sustained Therapeutic Effect of Etranacogene Dezaparvovec Gene Therapy in Hemophilia B - Data Presented at EAHAD 2022 (PR Newswire)
18.01.22	CSL BEHRING AG PUBLISHES OFFER PROSPECTUS ON PUBLIC TENDER OFFER FOR ALL PUBLICLY HELD SHARES OF VIFOR PHARMA LTD. (PR Newswire)
15.12.21	CSL Behring Receives Accelerated CHMP Assessment for Etranacogene Dezaparvovec for European Patients Living with Hemophilia B (PR Newswire)
07.12.21	New Data Supports the Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Reducing Influenza-Related Hospitalizations and Healthcare Costs in Older Adults (PR Newswire)
23.11.21	Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine (PR Newswire)
26.10.21	CSL Plasma Opens 300th Plasma Donation Center in United States (PR Newswire)
19.10.21	Seqirus Presents New Real-World Evidence Supporting Effectiveness of Differentiated Seasonal Influenza Vaccine Technologies at ISIRV-WHO Virtual Conference 2021 (PR Newswire)
19.10.21	Clinical Trial Milestones, Investments in aQIVc and sa-mRNA Influenza Vaccines and New Strategic Collaborations Among the Highlights from CSL R&D Day (PR Newswire)
15.10.21	Seqirus Receives FDA Approval of its Cell-Based Quadrivalent Influenza Vaccine, Expanding the Age Indication to Include Children as Young as Six Months (PR Newswire)
14.10.21	The New England Journal of Medicine Publishes First-of-its-Kind Study on Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) Efficacy in Children and Adolescents ≥2 to <18 Years of Age (PR Newswire)
04.10.21	Seqirus Awarded U.S. Government Contract to Develop Two Pandemic Influenza Vaccines (PR Newswire)
29.09.21	Seqirus Presents New Real-World Evidence Demonstrating Effectiveness of Cell-Based and Adjuvanted Seasonal Influenza Vaccines at IDWeek 2021 (PR Newswire)
26.08.21	CSL Plasma to Provide Flu Vaccines to U.S. Plasma Donors (PR Newswire)
19.08.21	Seqirus Announces Investment in Next-Generation Influenza Vaccine Technology, Self-Amplifying Messenger RNA (sa-mRNA) (PR Newswire)
09.08.21	The European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Task Force Has Strongly Recommended Subcutaneous Immunoglobulin (SCIg) for CIDP Maintenance Treatment (PR Newswire)
03.08.21	FDA Approves New BERINERT® (C1 Esterase Inhibitor, Human (Intravenous)) Administration Kit for Increased Patient Convenience (PR Newswire)
30.07.21	Seqirus Presents New Safety Data Demonstrating Safety of Cell-Based Seasonal Influenza Vaccine on Pregnancy Outcomes (PR Newswire)
27.07.21	Seqirus Begins Shipping Portfolio of Innovative Vaccines for the 2021/22 U.S. Influenza Season (PR Newswire)
24.06.21	CSLB Holdings Inc. -- Moody's announces completion of a periodic review of ratings of CSL Limited (Moodys)
14.06.21	Seqirus Co-Authors First Study to Assess Simultaneous Administration of Seasonal Influenza Vaccine and COVID-19 Vaccine Candidate (PR Newswire)
08.06.21	Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) To Be Covered Under Medicare Part B Effective July 18, Improving Access and Reducing Out-of-Pocket Costs for CIDP Patients (PR Newswire)
06.05.21	Moody's - Australian companies’ high cash holdings will normalise as business confidence returns (Moodys)
24.08.20	CSL Limited -- Moody's announces completion of a periodic review of ratings of CSL Limited (Moodys)
09.04.20	Australia's CSL stands by profit guidance due to strong demand for blood products (Reuters)
15.10.19	CSLB Holdings Inc. -- Moody's announces completion of a periodic review of ratings of CSL Limited (Moodys)
22.10.18	CSLB Holdings Inc. -- Moody's assigns P-2 commercial paper rating to CSL Limited; affirms company's ratings (Moodys)
15.08.17	CSL Limited -- Moody's takes rating action on CSL Limited (Moodys)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	77.24	3.12 %	K V
CieFinRichemont	137.85	2.68 %	K V
UBS Group	29.10	2.25 %	K V
Sika	216.40	1.64 %	K V
Part Grp Hldg	1’261.00	1.24 %	K V
Novartis	88.62	-0.45 %	K V
Alcon	75.92	-0.60 %	K V
Sonova Hldg	292.00	-1.48 %	K V
Nestle	73.28	-1.90 %	K V
Givaudan	3’844.00	-2.56 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu CSL Ltd (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten